• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?

作者信息

Zheng Yulong, Xu Nong, Zhou Jianying

机构信息

Department of Medical Oncology, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.

Department of Respiratory Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, 79 Qingchun Road, Hangzhou, Zhejiang, 310003, China.

出版信息

Lancet Oncol. 2013 Oct;14(11):e438. doi: 10.1016/S1470-2045(13)70412-1.

DOI:10.1016/S1470-2045(13)70412-1
PMID:24079869
Abstract
摘要

相似文献

1
Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC?介入化疗与厄洛替尼：晚期非小细胞肺癌患者可行的一线治疗选择？
Lancet Oncol. 2013 Oct;14(11):e438. doi: 10.1016/S1470-2045(13)70412-1.
2
Intercalated chemotherapy and erlotinib: a viable first-line option for patients with advanced NSCLC? - authors' reply.插入式化疗与厄洛替尼：晚期非小细胞肺癌患者的可行一线治疗选择？——作者回复
Lancet Oncol. 2013 Oct;14(11):e438-e439. doi: 10.1016/S1470-2045(13)70434-0.
3
Intercalated Dosing Schedule of Erlotinib and Docetaxel as a Therapeutic Strategy to Avoid Antagonism and Optimize Its Benefits in Advanced Non-Small-Cell Lung Cancer. A Randomized Phase II Clinical Trial.厄洛替尼与多西他赛的间歇给药方案作为一种治疗策略，用于避免晚期非小细胞肺癌中的拮抗作用并优化其疗效：一项随机II期临床试验。
Clin Lung Cancer. 2015 May;16(3):193-9. doi: 10.1016/j.cllc.2014.11.006. Epub 2014 Nov 23.
4
Beyond first-line NSCLC therapy: chemotherapy or erlotinib?非小细胞肺癌一线治疗之外：化疗还是厄洛替尼？
Lancet Oncol. 2012 Mar;13(3):225-7. doi: 10.1016/S1470-2045(12)70001-3. Epub 2012 Jan 24.
5
[Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].化疗与表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）联合与单纯化疗一线治疗晚期非小细胞肺癌的Meta分析
Zhongguo Fei Ai Za Zhi. 2016 Dec 20;19(12):837-846. doi: 10.3779/j.issn.1009-3419.2016.12.06.
6
Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.厄洛替尼对比化疗二线治疗晚期预后不良非小细胞肺癌患者的疗效和安全性（TITAN）：一项随机、多中心、开放性、III 期研究。
Lancet Oncol. 2012 Mar;13(3):300-8. doi: 10.1016/S1470-2045(11)70385-0. Epub 2012 Jan 24.
7
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer.厄洛替尼、培美曲塞和多西他赛在既往接受过治疗的晚期非鳞状非小细胞肺癌EGFR突变阴性患者中的回顾性疗效和安全性分析。
Lung Cancer. 2015 Sep;89(3):301-5. doi: 10.1016/j.lungcan.2015.06.017. Epub 2015 Jun 25.
8
Randomized Phase III Trial of Erlotinib versus Docetaxel in Patients with Advanced Squamous Cell Non-Small Cell Lung Cancer Failing First-Line Platinum-Based Doublet Chemotherapy Stratified by VeriStrat Good versus VeriStrat Poor. The European Thoracic Oncology Platform (ETOP) EMPHASIS-lung Trial.随机 III 期临床试验：厄洛替尼对比多西他赛在一线铂类双联化疗失败的晚期鳞状非小细胞肺癌患者中的应用，根据 VeriStrat 良好与 VeriStrat 不良进行分层。欧洲胸部肿瘤平台（ETOP） EMPHASIS-lung 试验。
J Thorac Oncol. 2017 Apr;12(4):752-762. doi: 10.1016/j.jtho.2016.12.017. Epub 2016 Dec 23.
9
Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of randomised controlled trials.晚期非小细胞肺癌的治疗：铂类化疗联合厄洛替尼还是单纯铂类化疗？一项随机对照试验的系统评价和荟萃分析
Med Oncol. 2015 Feb;32(2):471. doi: 10.1007/s12032-014-0471-0. Epub 2015 Jan 13.
10
Intercalated Chemotherapy and Epidermal Growth Factor Receptor Inhibitors for Patients With Advanced Non-Small-cell Lung Cancer: A Systematic Review and Meta-analysis.晚期非小细胞肺癌患者的插入式化疗与表皮生长因子受体抑制剂：一项系统评价与荟萃分析
Clin Lung Cancer. 2017 Jan;18(1):23-33.e1. doi: 10.1016/j.cllc.2016.08.006. Epub 2016 Oct 28.

引用本文的文献

1
Chemotherapy for Lung Cancer in the Era of Personalized Medicine.个性化医疗时代的肺癌化疗
Tuberc Respir Dis (Seoul). 2019 Jul;82(3):179-189. doi: 10.4046/trd.2018.0068. Epub 2018 Dec 20.
2
Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.化疗联合厄洛替尼与单纯化疗治疗晚期非小细胞肺癌的Meta分析
PLoS One. 2015 Jul 6;10(7):e0131278. doi: 10.1371/journal.pone.0131278. eCollection 2015.